Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688290 | PMC |
| http://dx.doi.org/10.1016/j.ijid.2020.11.180 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drugs and natural products for the treatment of COVID-19 during 2020, the first year of the pandemic.
Bol Med Hosp Infant Mex
March 2024
Facultad de Ciencias, Universidad Nacional Autónoma de México.
This work aimed to show which treatments showed efficacy against coronavirus disease 2019 (COVID-19); therefore, the results of 37 clinical trials started in 2020 and completed in 2021 are reviewed and discussed here. These were selected from databases, excluding vaccines, computational studies, in silico, in vitro, and those with hyperimmune sera from recovered patients. We found 34 drugs, one vitamin, and one herbal remedy with pharmacological activity against symptomatic COVID-19.
View Article and Find Full Text PDFNovaferon gene modification promotes NK92 cell anti-tumor activity.
Int Immunopharmacol
September 2023
Department of Pathogenobiology, The Key Laboratory of Zoonosis, Chinese Ministry of Education, College of Basic Medicine, Jilin University, Changchun 130021, Jilin, PR China; The Key Laboratory for Bionics Engineering, Ministry of Education, Jilin University, Changchun 130021, Jilin, PR China; Engineering Research Center for Medical Biomaterials of Jilin Province, Jilin University, Changchun 130021, Jilin, PR China; Key Laboratory for Health Biomedical Materials of Jilin Province, Jilin University, Changchun 130021, Jilin, PR China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi 830000, Xinjiang, PR China. Electronic address:
With significant developments in chimeric antigen receptor T-cell therapy, adoptive immunotherapy has unlocked new levels of treatment for malignancies. Natural killer (NK) cells are promising alternative immune effector cells for this strategy. Multiple anti-tumor therapies are largely dependent on type I interferon (IFN) signaling.
View Article and Find Full Text PDFPIONEER trial: favipiravir to treat moderate COVID-19.
Lancet Respir Med
May 2023
Schulich School of Medicine and Dentistry, Western University, London, ON N6A 5C1, Canada. Electronic address:
Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
J Infect Public Health
June 2021
Department of Pharmacology, Maharishi Markandeshwar Institute of Medical Sciences and Research, Mullana, Ambala, Haryana 133207, India.
Background: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been evaluated.
Methods: The databases were searched for comparative randomized controlled studies evaluating the efficacy and/or safety of lopinavir-ritonavir in COVID-19 patients.
Novaferon, treatment in COVID-19 patients.
Int J Infect Dis
February 2021
International Medicine Program, George Washington University School of Medicine and Health Sciences, Washington, DC, United States. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!